Research work · 2009
Merkel Cell Carcinoma
Stanley J. Miller, Murad Alam, James Andersen, Daniel Berg, Christopher Keram Bichakjian, Glen M. Bowen, Richard T. Cheney, Lewis Frank Glass, Roy C. Grekin, Dennis E. Hallahan, Anne Kessinger, Nancy Y. Lee, Nanette J. Liégeois, Daniel D. Lydiatt, Jeff M. Michalski, William H. Morrison, Kishwer S. Nehal, Kelly Carter Nelson, Paul Nghiem, Thomas E. Olencki
Journal of the National Comprehensive Cancer Network
Abstract
Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous tumor that combines the local recurrence rates of infiltrative non-melanoma skin cancer along with the regional and distant metastatic rates of thick melanoma.[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16] Several large reviews document the development of local recurrence in 25% to 30% of all cases of MCC, regional disease in 52% to 59%, and distant metastatic disease in 34% to 36%.1,16,17 MCC has a mortality rate that exceeds that of melanoma; 18 overall 5-year survival rates range from 30% to 64%.3,19 A history of extensive sun exposure is a